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Sporadic Creutzfeldt-Jakob disease (sCJD), the most frequent human prion disorder, is characterized by remarkable phenotypic
variability, which is influenced by the conformation of the pathologic prion protein and the methionine/valine polymorphic
codon 129 of the prion protein gene. While the etiology of sCJD remains unknown, it has been hypothesized that environmental
exposure to prions might occur through conjunctival/mucosal contact, oral ingestion, inhalation, or simultaneous involvement
of the olfactory and enteric systems. We studied 21 subjects with definite sCJD to assess neuropathological involvement of the
dorsal motor nucleus of the vagus and other medullary nuclei and to evaluate possible associations with codon 129 genotype and
prion protein conformation.The present data show that prion protein deposition was detected in medullary nuclei of distinct sCJD
subtypes, either valine homozygous or heterozygous at codon 129. These findings suggest that an “environmental exposure” might
occur, supporting the hypothesis that external sources of contamination could contribute to sCJD in susceptible hosts. Furthermore,
these novel data could shed the light on possible causes of sCJD through a “triple match” hypothesis that identify environmental
exposure, host genotype, and direct exposure of specific anatomical regions as possible pathogenetic factors.
1. Introduction
Prion diseases, or transmissible spongiform encephalo-
pathies (TSEs), are mammalian neurodegenerative disorders
that occur as sporadic, inherited, or iatrogenic forms [1].
The crucial pathogenetic event in TSEs is the conformational
conversion of the cellular prion protein, or PrPC, into PrPSc,
a self-propagating detergent-insoluble and protease-resistant
isoform [2]. In different prion strains, PrPSc shows distinct
sites of endogenous or exogenous proteolysis generating a
core fragment named PrP27-30 [3]. Sporadic Creutzfeldt-
Jakob disease (sCJD), the most common TSE, accounts for
about 85% of all human prion diseases and is characterized
by the absence ofmutations in the prion protein gene (PRNP)
and by lack of epidemiological evidence for iatrogenic,
dietary, or contact exposure to human or animal TSEs agents.
Six different molecular subtypes of sCJD are recognized,
based on the genotype at codon 129 of the PRNP, a site of
common M/V polymorphism, and two distinct conformers
of the pathological prion protein [4]. To date, the etiology of
sCJD remains unknown, and many investigations have been
devoted to assess whether the diseasemay follow endogenous
generation of prions or exogenous infection. If sCJD occurs
spontaneously, the disease might be initiated by somatic
mutations in PRNP at sites of ongoing neurogenesis, such as
the olfactory mucosa and the olfactory bulb, or by stochastic
misfolding of the PrPC in neural tissues. Conversely, if
exogenous infection is the cause, the gastrointestinal tract
(GIT), conjunctival or mucousmembranes, and the olfactory
system are the routes of entry to be taken into consideration.
Naturally occurring mammalian prion infections due to
foodborne contamination include Kuru, BSE, and vCJD [5].
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However, in these disorders the route of prions from the
GIT to the central nervous system remains largely unknown.
Experimental models show that after intragastric infection
neuroinvasion sequentially occurs via Peyer’s patches and
the enteric nervous system (ENS) [6, 7]. Neuroinvasion may
spread from the ENS through the splanchnic nerves to the
intermediolateral columns of the spinal cord or to the vagus
nerve to reach the nodose ganglion and the dorsal motor
nucleus vagus (DMNV) [8]. It is possible, however, that
distinct prion strains, especially lymphotropic agents, use
alternative routes for the neuroinvasion [9].
Recently, a so-called “dual hit” hypothesis has been
proposed for Parkinson’s disease (PD); this theory postulates
a simultaneous involvement of the olfactory system and
the DMNV, following aerosolic exposure to an unidentified
pathogen which spreads to the ENS after swallowing [10].
Intriguingly, the dual hit hypothesis seems to fit well with a
more general theory that could include prions.
Here we investigate the involvement of the DMNV and
other medullary nuclei in 21 consecutive definite sCJD cases
with different molecular subtypes.
2. Material and Methods
2.1. Demographic and Clinical Data. Twenty-one consecutive
unrelated subjects (10 males and 11 females) with definite
sCJD were examined in the study. Clinical data and relevant
hospital records, including MRI, EEG, and CSF assessment
[11], were obtained from the treating physicians in Neu-
rological and Geriatric Units of Veneto (17), Trentino-Alto
Adige (1), Friuli-Venezia Giulia (2), and Lombardia (1) in
Northern Italy. All data were obtained after the permission
of the local competent legal and ethical authorities. Brains
obtained at autopsy were collected during the period 1998–
2003 at Neuropathology Unit, University of Verona, Italy.
None of these sCJD cases had a history of possible
external or iatrogenic exposure. The duration of disease
was calculated from the onset of the first symptoms until
death. Neurological signs were classified as occurring at
“clinical presentation” when observed within the first two
weeks of disease. All main demographic and clinical data are
summarized in Table 1.
2.2. Genetic Studies and PrPSc Typing. The sequencing of
the coding region of PRNP was performed in all patients.
None presented a pathogenetic mutation of PRNP. DNA was
extracted from frozen brain tissues. Search for PRNP muta-
tions andM/V polymorphism at codon 129 was performed as
previously described [12].
Typing of PrPSc was done as previously described and
classified as type 1 and type 2, according to Parchi et al. [4].
2.3. Tissue Sampling and Immunohistochemistry. In all cases,
the medulla oblongata was sampled at two levels: at the
caudal portion of the inferior olive and midway the inferior
olive. Eight 𝜇m thick paraffin sections were deparaffinized,
rehydrated, treated with 98% formic acid for 1 h at room
temperature, and then autoclaved with 1.5mM HCL for
10 minutes at 121∘C. After rinsing with distilled H
2
O and
phosphate buffered saline (PBS) sections were saturated
with 10% goat serum in PBS for 20 minutes, washed in
PBS, and incubated overnight at 4∘C with anti-PrP mon-
oclonal antibody (3F4, Dako, Denmark) diluted at 1 : 2000
in PBS. Preparations were then incubated with a biotiny-
lated goat anti-mouse secondary antibody 1 : 2000 for 60
minutes at room temperature and finally with the avidin-
biotin-peroxidase complex (Vectastain ABC-Elite kit, Vector
Laboratories). Diaminobenzidine tetrachloride was used to
visualize the immunoreactivity. Subsequently, sections were
counterstained with hematoxylin and then dehydrated. The
presence of gliosis was assessed with polyclonal rabbit anti-
GFAP antibody (Dako, Denmark). Additionally, all the sec-
tions were stained with hematoxylin and eosin (H&E). Semi-
quantitative assessment of PrPSc deposition, spongiosis, and
gliosis was rated as follows: negative (−), mild (±), moderate
(+), and severe (++) by three independent neuropathologists.
The perihypoglossal nuclei (PHN, including nucleus
praepositus, nucleus intercalatus, and the nucleus of Roller)
and the inferior olivary complex (IOC, including the medial
and dorsal accessory olive and the inferior olive) were
considered as whole groups (Figure 1).
2.4. Statistics. Statistic columns were calculated to obtain the
mean age at death, the mean duration of disease, and the
percentages of PrPSc positivity, respectively, in DMNV, HN,
PHN, and IOC of all 21 subjects.
Statistical analyses were also performed clustering the
whole sample of subjects in two main groups: patients
without V (Group 1) and patients with V (Group 2), that is,
subjects with at least one V allele in the genotype.
Parametric analyses, as Student’s t-tests and one-way
analysis of variance,were performed to compare themean age
at death (years) and the mean duration of disease (months)
between Group 1 and Group 2. Nonparametric analyses, as
Pearson’s 𝜒2 tests, were used to verify possible significant
associations between the PrPSc positivity in DMNV, HN,
PHN, and IOC and Group 1 or Group 2. Pearson’s 𝜒2 tests
were also used to test possible associations between prion
positivity of DMNV, HN, PHN, IOC, and, respectively, PrPSc
type 1 and PrPSc type 2, independently of the M/V genotype.
3. Results
Allmain clinical andneuropathological data are summarized,
respectively, in Tables 1 and 2.
The column statistics showed a mean age equal to 64.7 ±
1.5SE years (range: 48–79). The average disease duration was
9.8 ± 2.1SE months (range: 3–48). The percentage of PrPSc
positivity in each nucleus was as follows: 47.6% (10 out of
21 subjects) for DMNV, 33.3% (7 out of 21 subjects) for HN,
52.3% (11 out of 21) for PHN, and 57.1% (12 out of 21) for IOC.
There was no statistical difference in terms of percentages
PrPSc positivity across all nuclei.
In terms of standard neuropathological assessment for
CJD (gliosis and spongiosis), all examined cases, indepen-
dently of the M/V genotype or PrPSc type, showed low
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Table 1: Main demographic and clinical data of all subjects in study. Group 2 is the second part of the table.
Case
number
sCJD
molecular type
Age at
death/gender
Duration of
disease (months) Clinical signs at onset Clinical signs at late clinical evaluation
1 MM1 70/f 3 Confusion Myoclonus, ataxia, gait disorders,paraphasia, and coma
2 MM1 70/f 4 Cognitive impairment Progressive cognitive impairment
3 MM1 63/m 6 Irritability,restlessness
Myoclonus, ataxia, motor perseverations,
amnesia, loss of spontaneous movement,
and aphasia
4 MM1 52/m 3
Amnesia, diplopia,
and involuntary
movements
Myoclonus, involuntary movements,
bradikinesia, cognitive impairment,
visual hallucinations, and aphasia
5 MM1 70/f 8 Confusion,hallucinations
Myoclonus, ataxia, progressive dementia,
and coma
6 MM1 65/m 3 Confusion, gaitdisorders
Myoclonus, plastic hypertonia, ataxia,
aphasia, and progressive cognitive
impairment
7 MM1 71/f 16 Objective vertigo
Myoclonus evoked by auditory and tactile
stimuli, ataxia hallucinations,
paresthesias, diplopia, alien hand, and
dementia
8 MM1 62/f 11 Ataxia, speechdisorder
Myoclonus, behavioral changes
(aggression), confusion, dysphagia, and
spasticity
9 MM1 60/m 2 Confusion
Myoclonus, insomnia, visual
hallucinations, apraxia, and cognitive
impairment
10 MM1 69/m 6 Visual disorders Myoclonus, ataxia, and cognitiveimpairment
11 MM2 61/f 11
Amnesia, impaired
attention, and
disorientation in time
and place
Myoclonus, rigidity, alteration
production and comprehension of the
speech, agitation, altered sleep wake
rhythm, and behavioral disorders
12 MM2 59/m 18 Depression
Amnesia, reduced ideational, ataxia
insomnia, headache, cognitive
impairment, amnesia, and reduced
ideation
13 MV1 66/m 17 Aphasia
Tremor, involuntary movements,
dysarthria, comprehension deficit, and
akinetic mutism
14 MV2 79/m 6 Gait disorders,drowsiness
Myoclonus, motor slowing, ataxia, and
impaired eye movements upwards
15 MV2 61/f 11 Ataxia Myoclonus, ataxia dementia, and aphasia
16 MV2 48/m 48
Irritability, apathy,
delusions, and
paranoia
Rigidity, hypokinesia, visuospatial and
memory disorders, and cognitive
impairment
17 VV2 71/f 5 Dizziness
Myoclonus, photophobia, amnesia,
confusion, cognitive impairment,
drowsiness, and anxiety
18 VV2 64/f 13 Ataxia, cognitiveimpairment
Involuntary movements, ataxia
depression, cognitive impairment, and
delirium
19 VV2 62/f 3 Ataxia Myoclonus, visual hallucinations, andgaze deviation to the left
20 VV2 68/f 6 Balance disorders
Bradikinesia, myoclonus, ataxia,
disorders of attention, difficulty writing,
and depression
21 VV2 69/f 6 Cognitive decline,myoclonus Akinetic mutism
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Inferior olivary complex
(a)
Perihypoglossal nuclei
(b)
Figure 1: (a) Anti-PrPSc staining of the inferior olivary complex (IOC): inferior olivary nucleus (A) and accessory olivary nucleus (B) in
patient number 14; (b) shows perihypoglossal nuclei: nucleus praepositus (A), nucleus intercalatus (B), and the nucleus of Roller (C), stained
with anti-PrP antibody in the same case (bar = 200 𝜇m).
Table 2: Quantitative neuropathological analysis of spongiosis, gliosis, and PrPSc deposits in all the examined nuclei according to the different
genotypes. The main pattern of PrPSc deposits is also reported. Group 2 is the second part of the table.
Case
number
sCJD
molecular type
DMNV HN PHN IOC
S G PrPSc S G PrPSc S G PrPSc S G PrPSc
1 MM1 ± ± − ± ± − − ± − − ± −
2 MM1 − ± − − − − − − − − ± −
3 MM1 + + + (syn.) ± + + (syn.) − ± + (syn.) − ± + (syn.)
4 MM1 ± ± − + + − + + − − − −
5 MM1 ± − − − − − − − + (syn.) − − + (syn.)
6 MM1 − − − − − − − − − − − −
7 MM1 ± ± − ± ± − ± ± − − ± + (syn.)
8 MM1 + + − ± ± − − − − − − −
9 MM1 + ++ − + ± − − − − − − −
10 MM1 ± − − + ± − − ± − − − −
11 MM2 + ± − − − − − − − − − −
12 MM2 ± ± − ± ± − − − − − − −
13 MV1 ++ ++ ± + + − ± ± ± (syn.) − ± + (syn.)
14 MV2 + + + (syn.) ± + + (syn.) ± + + (syn.) − ± + (syn.)
15 MV2 ± ± + (syn.) ± ± + (syn.) ± ± + (syn.) − + + (syn.)
16 MV2 − − + (syn.) + ± + (gran.,pl.-like) + + + (syn.) − ± + (syn.)
17 VV2 ± ± + (syn.,periaxo.) ± ±
+ (syn.,
periaxo.) ± ±
+ (syn.,
periaxo.) − ±
+ (syn.,
periaxo.)
18 VV2 ± ++ ± ± + ± + + + − + +
19 VV2 ± ± + − − ± − − + − ± +
20 VV2 ± ± + (syn.) − ± − − ± + (syn.) − ± + (syn.)
21 VV2 ± +
+ (syn.,
gran.,
periaxo.)
± + − ± + + (syn., gran.,periaxo.) − ± + (syn.)
DMNV: dorsal motor nucleus of the vagus; HN: hypoglossal nucleus; PHN: perihypoglossal nuclei; IOC: inferior olivary complex; S: spongiosis; G: gliosis;
PrPSc: prion protein;syn.: synaptic; gran.: granular; periaxo.: periaxonal; pl.-like: plaque-like; −: negative; ±: mild; +: moderate; ++: severe.
level or absence of spongiosis in the medulla oblongata. In
particular no spongiosis was present in IOC, and variable
degrees of gliotic reaction were observed in all other nuclei
(Figures 2, 3, 4, and 5). There was no linear correlation
between PrPSc positivity, gliotic reaction, and spongiosis
across all nuclei. As for the prevalent histological type of
PrPSc deposition, synaptic and granular deposits had a major
frequency compared to the other pattern.
The statistical analyses did not show significant differ-
ences between Group 1 and Group 2, respectively, subjects
with and without V, in terms of mean age at death (Group 1:
64.3±1.6SE, Group 2: 65.3±2.8SE;𝑃 = 0.75), and duration of
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Figure 2:MM1 PrPSc-negative patients.This figure shows the IOC,DMNV,HN, and PHN stained for PrPSc, GFAP, andH&E inMM1 number
2 case. PrPSc immunostaining results negative in examined nuclei (bar = 50𝜇m).
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Figure 3: MM1 PrPSc-positive patients. The figure shows the synaptic pattern of PrPSc deposits in IOC, DMNV, HN, and PHN in MM1
number 3 patient. GFAP and H&E staining are also reported (bar = 50 𝜇m).
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Figure 4: MV2 PrPSc-positive patients. The figure shows a prevalent synaptic pattern of PrPSc deposits in the IOC, DMNV, HN, and PHN in
MV2 number 16 patient. Also granular and plaque-like deposits are evident. GFAP and H&E staining are reported below (bar = 50𝜇m).
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Figure 5: VV2 PrPSc-positive patients. The figure shows PrPSc, GFAP, and H&E staining in IOC, DMNV, HN, and PHN in VV2 number 21
patient. The synaptic and granular patterns of PrPSc deposits are evident (bar = 50 𝜇m).
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disease (Group 1: 7.5±1.5SE; Group 2: 12.7±4.6SE; 𝑃 = 0.24;
𝐹 = 6.7).
Strikingly, the analysis showed significant association
(𝑃 < 0.0001) betweenGroup 2 andPrPSc positivity inDMNV,
HN, PHN, and IOC compared to Group 1.
However, it appears that the polymorphic codon V is
associated with prion positivity of all nuclei more than
PrPSc type 2. In fact, the presence of PrPSc type 2 appeared
neither sufficient nor necessary to determine prion protein
deposition as demonstrated by MM2 cases (case 11 and case
12). As confirmation, case 13 showed that the presence of V
in the absence of PrPSc type 2 was sufficient for determinate
prion positivity in all examined nuclei.
4. Discussion
Previous investigations on sCJD pathology showed that the
brainstem was essentially spared from the disease process in
most of the examined cases [13]. In addition, PrPScwasmostly
absent in series of investigated cases, with a single exception
[14]. However, some evidences of variable spongiotic changes
of the quadrigeminal plate, substantia nigra, and pontine
nuclei have been rarely reported [15].
In the present study we show that PrPSc deposition occurs
in the medulla of subjects affected by sCJD. In particu-
lar, PrPSc deposition was preferentially observed in sCJD
subjects with MV2 and VV2 molecular subtypes. Among
subjects with MM1/MV1 subtype, 4 cases out of 11 showed
PrPSc deposition in distinct medullary nuclei, although the
majority of cases were negative (Table 2). The assessment
of the pathological score (gliosis and spongiosis) did not
show major differences between cases with or without PrPSc
deposition, since only low-to-mild and unspecific changes
could be observed in almost all investigated medullary
locations, either at the level ofmedullary nuclei or in thewhite
matter. This finding confirms previous observations showing
that deposition of PrPSc in the brainstem is not always
accompanied by the sequential appearance of spongiform
changes, neuronal loss, and astrocytosis, as observed in other
CNS regions. These observations suggest also the relative
resistance of the brainstem to the pathological changes
induced by abnormal PrPSc.This peculiaritymay also account
for the lack of distinct clinical features, that is, focal mid-
brain signs, even in cases showing prevailing involvement
of medullary nuclei. Differences in the pathological profiles
were not accounted by distinct clinical features or disease
duration.More importantly, the ongoing findings suggest that
specific brainstem structures may represent a possible site for
the rostral spreading of prions.
It could be hypothesized that only the intimate molecular
interaction between PrPSc type and a specific genotype could
determine the risk of brainstem prion deposition that triggers
a transsynaptic mechanism of pathologic spreading.
Our study is partially supported by a previous investiga-
tion on a large series of definite sCJD cases, where subtypes
MM1 (the majority), MV1, and VV1 were characterized by
sparing of the brainstem and almost complete absence of
the pathological prion protein [16]. On the other side, the
MM2-thalamic phenotype showed moderate/severe pathol-
ogy in periaqueductal medullary gray and inferior olives.
In MV2 and VV2 subtypes a moderate-to-severe patholog-
ical score, quantified according to the combined extent of
spongiosis, gliosis, and neuronal loss, was observed in the
substantia nigra, periaqueductal gray, locus coeruleus, and
periventricular medullary gray and inferior olives.
In comparison with these data, the lack of medullary
involvement in MM2-cortical subtype and the positivity
of MV1 subtype reported in our analysis may support the
dominant effect of synonymous or nonsynonymous valine
expression at PRNP codon 129 over the agent strain in
determining the phenotype. However, in previous studies
we have demonstrated that the combination of the PrPSc
core fragment and truncated fragments shows two different
signatures between type 2 PrPSc detected in MM subjects of
the cortical subtype and that found in MV and VV subjects
[3].
In alternative, as based on the M/V polymorphism at
the codon 129 of the PRNP gene, it is possible that the
presence of V could be, per se, an important genotypic factor
associated with PrPSc deposition in specific brainstem nuclei.
The present data are in line with previous observations that
V homozygosity favors the occurrence of iatrogenic CJD
(iCJD) when exposure to external contaminated material
occurs [17–19] and could be also a determinant of sCJD
by prion-contaminated soil [20] or by mucosal/olfactory
contact with the environment [21]. Other than representing
a risk factor for peripheral selection of PrPSc, V expression
could be a major determinant of the selective vulnerability of
brainstem nuclei DMNV or HN that are directly connected
with the external environment and could be sites of entrance,
or transmission, of an exogenic neurotrophic/prion toxic
factor. These regions are indeed in direct contact with
possible “hostile” outer environments fromwhere both olfac-
tory/oropharyngeal/gastroenteric systems could be “contam-
inated.”
It has been already hypothesized that environmental
exposure to prions may theoretically occur through con-
junctival/mucosal contact, olfactory inhalation, and oral
ingestion [21–25]. Neuropathological studies have shown that
Kuru is characterized by significant brainstem pathology,
with severe spongiosis and gliosis of periaqueductal grey
and quadrigeminal plate, and less intense changes in the
basis pontis, central tegmental area, and inferior olivary
nuclei, accompanied by synaptic-type PrPSc deposition. On
the contrary, in vCJD spongiosis, gliosis, and dense synaptic
PrPSc deposition mainly occur within the superior colliculi,
substantia nigra, and pontine nuclei. Intriguingly, neuronal
loss, spongiosis, and dense PrPSc deposition are also found
within the dorsal motor vagal nuclei and the inferior olivary
nuclei [26, 27]. These findings are in keeping with experi-
mental evidence showing that, in sheep orally inoculatedwith
BSE, PrPSc is first detected in the dorsal motor nucleus of the
vagus, hence suggesting amajor role of the vagus nerve circuit
in neuroinvasion [28]. In addition, these novel findings could
match with the “dual hit” hypothesis formulated by Braak
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for PD [10]. A double prion attack could be also possible
in sCJD. The anterograde-way, via olfactory system, and the
retrograde-way, via GIT and preganglionic vagal fibers, could
be the main anatomical substrates through which the prions
could spread out to the rest of the nervous system.Our results
suggest that this possibility is real one in susceptible hosts: the
V carriers. Moreover, as suggested by Braak, a direct access
to the medulla via the viscerosensory fibers of the vagus in
the pharynx or trigeminal nerve is not compatible with the
sparing of the solitary tract. We agree on this point since
we never observed in our sCJD series prion positivity in
the solitary tract, not in MM1/MV1, MM2, MV2, or VV2
cases. From this, we speculate that a larger aetiopathogenetic
hypothesis could be formulated for sCJD at least (and
probably for PD also), named “triple match,” including the
toxic environmental exposure, the host genotype, and the
direct contact with “hot” anatomical regions (i.e., olfactory
fibers, vagal fibers, and hypoglossal fibers).
As final finding, it is important to underline that the
definition of the lesion profiles, including medulla oblongata,
and the regional distribution of the pathological prion protein
in brains of subjects with sCJD is important for evaluating
cases with suspected environmental origin such as for the
epidemiological surveillance of the disorder. In conclusion
our data suggest a possible association between the presence
of V at codon 129 and deposits of PrPSc in the nuclei of
the medulla oblongata related to the gastrointestinal and
olfactory systemandhighlight a probable distinctmechanism
of PrPSc spreading in patients with sCJD and V at codon 129
of PRNP gene.
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